In the event of non-compliance with the obligations set out in article L. 5124-20 and in this chapter, which may be identified following an inspection, the Director General of the Agency may prohibit the brokering activity for a maximum period of six months.
Except in cases of urgency, the decision to prohibit practice may only be taken after the person carrying out the activity of brokering medicinal products has been invited to present his/her observations.
If, at the end of the prohibition period, the person carrying out the activity of drug brokerage has not complied with the applicable rules, the Director General of the Agency may impose a new prohibition under the same conditions.